Analyst Perspectives | RBC Capital maintains an Outperform rating with price targets ranging from $61 to $68, reflecting optimism despite near-term hurdles |
Financial Uncertainty | Uncover the factors behind QuidelOrtho's suspended FY2024 guidance, including COVID-19 sales volatility and its effect on investor confidence |
Product Launch Delay | Delve into the implications of Savanna's postponed US launch to 2025, balancing short-term revenue impacts against long-term growth prospects |
Strategic Pivot | Explore QuidelOrtho's $100M cost rationalization plan and its potential to enhance operational efficiency and medium-term margins amid market challenges |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Metrics to compare | QDEL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipQDELPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.5x | 29.5x | −0.6x | |
PEG Ratio | 0.00 | 0.29 | 0.00 | |
Price / Book | 0.9x | 3.2x | 2.6x | |
Price / LTM Sales | 1.0x | 3.0x | 3.2x | |
Upside (Analyst Target) | 27.5% | −0.7% | 43.9% | |
Fair Value Upside | Unlock | 5.0% | 7.8% | Unlock |